Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: infectious disease vaccines - Lumos Pharma

Drug Profile

Research programme: infectious disease vaccines - Lumos Pharma

Alternative Names: Alpha-Gal influenza virus vaccines; Influenza virus vaccine - Lumos Pharma; Zika virus vaccine - Lumos Pharma

Latest Information Update: 21 May 2020

At a glance

  • Originator NewLink Genetics Corporation
  • Developer Lumos Pharma
  • Class Influenza virus vaccines; Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza virus infections; Zika virus infection

Most Recent Events

  • 28 Mar 2020 No recent reports of development identified for research development in Zika-virus-infection in USA (Parenteral)
  • 28 Aug 2018 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in USA (Parenteral)
  • 02 Feb 2016 Early research in Zika virus infection in USA (Parenteral)

Development Overview

Introduction

Lumos Pharma (previously NewLink Genetics) is developing vaccines based on the its proprietary HyperAcute® vaccine technology, which involves α(1,3)-galactosyltransferase (αGal) gene modification of vaccines, including virus-like particle vaccines and recombinant vaccines. The αGal gene codes for an enzyme that adds certain sugars to proteins and lipids in the cell membranes of lower mammals. Humans do not express these sugar moieties and therefore develop a strong immunological response to cells expressing these modifications. αGal-modification of vaccines enhances immune responses without the use of an adjuvant. NewLink Genetics has investigated the feasibility of αGal of various influenza vaccines, but the company has stated that the HyperAcute® vaccine technology is not limited to influenza vaccines. Preclinical development is underway in the US.

Lumos Pharma is also developing a Zika vaccine candidate for the treatment of Zirus virus infections [1] .

As at August 2018, no recent reports of development had been identified for preclinical development in Influenza-virus-infections (Prevention) in USA (Parenteral).

As at March 2020, no recent reports of development had been identified for research development in Zika-virus-infection in USA (Parenteral).

In March 2020, NewLink Genetics Corporation and Lumos Pharma merged to form Lumos Pharma [2] .

Key Development Milestones

In February 2016, NewLink Genetics initiated a Zika vaccine programme to develop a vaccine candidate for the treatment of Zika virus infection [1] .

A presentation on the efficacy of αGal-modified influenza vaccines was made at the XVth International Congress of Virology in July 2014 [3] .

Drug Properties & Chemical Synopsis

  • Route of administration Parenteral
  • Formulation unspecified
  • Class Influenza virus vaccines, Viral vaccines, Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • WHO ATC code

    J07B-B (Influenza vaccines)

    J07B-X (Other viral vaccines)

  • EPhMRA code

    J7E (Viral Vaccines)

    J7E1 (Influenza vaccines)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
Influenza virus infections - Prevention No development reported (Preclinical) USA Parenteral / unspecified Lumos Pharma 28 Aug 2018
Zika virus infection - - No development reported (Research) USA Parenteral / unspecified Lumos Pharma 28 Mar 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
NewLink Genetics Corporation Originator USA
Lumos Pharma Owner USA

Development History

Event Date Update Type Comment
28 Mar 2020 Phase Change - No development reported No recent reports of development identified for research development in Zika-virus-infection in USA (Parenteral) Updated 28 Mar 2020
18 Mar 2020 Company Involvement NewLink Genetics Corporation has merged with Lumos Pharma to form Lumos Pharma Updated 21 May 2020
28 Aug 2018 Phase Change - No development reported No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in USA (Parenteral) Updated 28 Aug 2018
02 Feb 2016 Phase Change Early research in Zika virus infection in USA (Parenteral) Updated 05 Feb 2016
27 Aug 2014 Phase Change - Preclinical Preclinical trials in Influenza virus infections (Prevention) in USA (Parenteral) Updated 27 Aug 2014

References

  1. NewLink Genetics Corporation Announces Project to Develop New Treatment Options for the Zika Virus.

    Media Release
  2. NewLink Genetics Stockholders Approve Merger with Lumos Pharma.

    Media Release
  3. NewLink Genetics to Present at the XVIth International Congress of Virology.

    Media Release
Back to top